Joseph M. Limber Acquires 5,243 Shares of XOMA Co. (NASDAQ:XOMA) Stock

XOMA Co. (NASDAQ:XOMA - Get Free Report) Director Joseph M. Limber bought 5,243 shares of XOMA stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average cost of $25.60 per share, for a total transaction of $134,220.80. Following the purchase, the director now owns 10,000 shares in the company, valued at $256,000. This represents a 110.22 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

XOMA Trading Up 1.4 %

Shares of XOMA stock traded up $0.27 during trading hours on Friday, reaching $19.97. The stock had a trading volume of 15,021 shares, compared to its average volume of 27,545. The firm has a market capitalization of $238.70 million, a price-to-earnings ratio of -5.74 and a beta of 1.00. XOMA Co. has a 1 year low of $18.35 and a 1 year high of $35.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm has a 50 day simple moving average of $22.14 and a two-hundred day simple moving average of $26.20.

XOMA (NASDAQ:XOMA - Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. As a group, equities research analysts anticipate that XOMA Co. will post -1.41 earnings per share for the current year.

Remove Ads

Institutional Investors Weigh In On XOMA

Several institutional investors and hedge funds have recently modified their holdings of XOMA. BNP Paribas Financial Markets boosted its holdings in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock worth $43,000 after acquiring an additional 795 shares during the period. State Street Corp boosted its stake in shares of XOMA by 1.2% in the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock valued at $3,783,000 after purchasing an additional 1,754 shares during the period. Barclays PLC boosted its stake in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock valued at $298,000 after purchasing an additional 8,447 shares during the period. Geode Capital Management LLC grew its holdings in XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock valued at $4,840,000 after purchasing an additional 1,138 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company's stock worth $291,000 after buying an additional 1,699 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. StockNews.com upgraded XOMA from a "sell" rating to a "hold" rating in a research report on Friday. HC Wainwright reaffirmed a "buy" rating and set a $104.00 price target on shares of XOMA in a research note on Friday, March 28th.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.